tiprankstipranks
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

1,799 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
11Ratings
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$121.11
▲(64.48% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $121.11 with a high forecast of $190.00 and a low forecast of $97.00. The average price target represents a 64.48% change from the last price of $73.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","191":"$191","95.75":"$95.8","127.5":"$127.5","159.25":"$159.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$190.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$121.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$97.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,95.75,127.5,159.25,191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.9,82.83076923076923,91.76153846153846,100.69230769230771,109.62307692307692,118.55384615384617,127.4846153846154,136.41538461538462,145.34615384615387,154.27692307692308,163.2076923076923,172.13846153846154,181.06923076923078,{"y":190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.9,77.53153846153846,81.16307692307693,84.79461538461538,88.42615384615385,92.0576923076923,95.68923076923078,99.32076923076923,102.9523076923077,106.58384615384615,110.21538461538461,113.84692307692308,117.47846153846154,{"y":121.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.9,75.67692307692309,77.45384615384616,79.23076923076924,81.00769230769231,82.78461538461539,84.56153846153846,86.33846153846154,88.11538461538461,89.8923076923077,91.66923076923077,93.44615384615385,95.22307692307692,{"y":97,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85,"date":1686873600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.7,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.66,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.69,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.6,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.14,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.31,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.82,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.42,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.25,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.8,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.9,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$190.00Average Price Target$121.11Lowest Price Target$97.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners
$100.00
Buy
35.81%
Upside
Reiterated
05/06/24
Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials
TD Cowen
$120.00
Buy
62.98%
Upside
Reiterated
03/08/24
TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
UBS
$107.00
Buy
45.32%
Upside
Reiterated
02/21/24
Axsome Therapeutics price target lowered to $107 from $111 at UBSAxsome Therapeutics price target lowered to $107 from $111 at UBS
Cantor Fitzgerald
$108.00
Buy
46.68%
Upside
Reiterated
02/20/24
Axsome Therapeutics (AXSM) PT Raised to $108 at Cantor FitzgeraldCantor Fitzgerald analyst Charles C. Duncan raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $108.00 (from $103.00) while maintaining a Overweight rating.
Ladenburg Thalmann & Co.
$173.00
Buy
134.96%
Upside
Reiterated
01/16/24
Axsome Therapeutics price target raised to $173 from $162 at LadenburgAxsome Therapeutics price target raised to $173 from $162 at Ladenburg

Best Analysts Covering Axsome Therapeutics

Which Analyst Should I Follow If I Want to Buy AXSM and Sell After:
1 Month
Charles DuncanCantor Fitzgerald
Success Rate
12/18 ratings generated profit
67%
Average Return
+31.71%
reiterated a buy rating 4 months ago
Copying Charles Duncan's trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +31.71% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Charles DuncanCantor Fitzgerald
Success Rate
12/18 ratings generated profit
67%
Average Return
+56.93%
reiterated a buy rating 4 months ago
Copying Charles Duncan's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +56.93% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Joon LeeTruist Financial
Success Rate
11/15 ratings generated profit
73%
Average Return
+43.24%
reiterated a buy rating last month
Copying Joon Lee's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +43.24% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
12/16 ratings generated profit
75%
Average Return
+8.86%
reiterated a buy rating 11 days ago
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +8.86% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Feb 24
Mar 24
Apr 24
May 24
Jun 24
Strong Buy
9
10
16
18
16
Buy
22
25
20
18
12
Hold
1
2
1
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
37
37
39
30
In the current month, AXSM has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is $121.11.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$1.30 with a range of -$1.67 to -$0.91. The previous quarter’s EPS was -$1.44. AXSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year AXSM has Underperformed its overall industry.
Next quarter’s earnings estimate for AXSM is -$1.30 with a range of -$1.67 to -$0.91. The previous quarter’s EPS was -$1.44. AXSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year AXSM has Underperformed its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $86.85M with a range of $80.70M to $95.00M. The previous quarter’s sales results were $75.00M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.58% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s sales forecast for AXSM is $86.85M with a range of $80.70M to $95.00M. The previous quarter’s sales results were $75.00M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.58% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is $121.11.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 64.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s price target?
            The average price target for Axsome Therapeutics Inc is $121.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $190.00 ,the lowest forecast is $97.00. The average price target represents 64.48% Increase from the current price of $73.63.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis